MedTrace Logo

A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects

NCT06057103 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-11-04

No results posted yet for this study

Summary

The primary object of this study is evaluating the effect of multiple oral oseltamivir phosphate capsules on the pharmacokinetic profile of the active metabolite ZX-7101 after a single oral administration of ZX-7101A tablet in healthy Chinese adult subjects.

The seongdary object is evaluating combined or uncombined multiple oral oseltamivir phosphate in healthy Chinese adult subjects.

Conditions

  • Drug Interaction

Interventions

DRUG

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

DRUG

Oseltamivir

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

DRUG

ZX-7101A and Oseltamivir

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

DRUG

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

DRUG

Oseltamivir

Oseltamivir phosphate capsule was administered as a single drug, 75 mg twice daily, for 5 days,Oral

DRUG

ZX-7101A and Oseltamivir

ZX-7101A tablet (80mg, single dose) was combined with oseltamivir phosphate capsule (75 mg twice daily),Oral

DRUG

ZX-7101A

ZX-7101A Tablets single dose tablet, 80 mg, Oral

Sponsors & Collaborators

  • Nanjing Zenshine Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-28
Primary Completion
2023-12-05
Completion
2024-04-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06057103 on ClinicalTrials.gov